First human trial of CTX-187 for healthy people and those with chronic infection
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: You are between 18 and 65 years old, in good health, with a BMI between 18 and 32.
- You must weigh more than 50 kg (about 110 pounds).
- For people with bronchiectasis: You are between 18 and 75 years old and have a confirmed diagnosis of bronchiectasis.
- You have had a Pseudomonas aeruginosa infection in your lungs in the past year and still have it now.
- You are not taking new antibiotics for Pseudomonas that started in the last 3 months.
- You do not have cystic fibrosis, active tuberculosis, or unstable heart, lung, or other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug given through an IV to see if it can reduce lung infections and flare-ups in people with bronchiectasis who have a chronic pseudomonas infection. Participation may help improve symptoms and quality of life.
This study tests a new medication called AZD0292 for people with bronchiectasis who have a long-term Pseudomonas infection. It aims to see if the drug can reduce flare-ups and improve lung health.
This trial tests an inhaled medication for adults with bronchiectasis, a lung condition that causes chronic cough and mucus. The goal is to see if the drug is safe and helpful in reducing symptoms and infections.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
Hear when a new Bronchiectasis Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.